Category Archives: Myocardial Infarction

The Myocardial Infarction Drug Market report includes overview, which interprets value chain structure, industrial environment, regional analysis, applications, market size, and forecast. This is a latest report, covering the current COVID-19 impact on the market. The pandemic of Coronavirus (COVID-19) has affected every aspect of life globally Continue reading →

New research was presented at Kidney Week 2020 Reimagined, the virtual annual meeting of the American Society of Nephrology. The features below highlight some of the studies that emerged from the conference. Although chronic kidney disease has been shown to be associated with adverse outcomes in patients with established cardiovascular disease (CVD) or diabetes, medications to treat CVD in patients with low estimated glomerular filtration rate (eGFR) may be ineffective Continue reading →

October 26, 2020 07:00 ET | Source: Amarin Corporation plc Patients with decreased renal function prior to treatment with VASCEPA or placebo had higher rates of cardiovascular events than the overall population studied in REDUCE-IT REDUCE-IT patients with decreased renal function prior to treatment showed similarly favorable relative risk reductions and numerically greater absolute risk reductions in cardiovascular events in comparison with the overall patient population Consistent and robust benefit in cardiovascular outcomes seen in both prespecified and post hoc exploratory analyses across a broad range of baseline eGFR (estimated Glomerular Filtration Rate) categories DUBLIN, Ireland and BRIDGEWATER, N.J., Oct. 26, 2020 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced the first presentation of REDUCE-IT RENAL results at American Society of Nephrology (ASN) Kidney Week 2020, held virtually from October 22 October 25 Continue reading →

This article was originally published here J Am Heart Assoc. Continue reading →

Ticagrelor and prasugrel may have altered efficacy for the treatment of acute coronary syndrome (ACS) in patients with diabetes mellitus (DM), according to study results published in the Journal of the American College of Cardiologists: Cardiovascular interventions. These findings were from a pre-specified analysis of data from the Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment 5 trial in which patients (N=4016) who were hospitalized for ACS were randomly assigned to receive 180 mg ticagrelor followed by a 90 mg maintenance dose twice daily (n=2011) or 60 mg prasugrel followed by a maintenance dose of 10 mg once daily (n=2005) Continue reading →

The Myocardial Infarction Drug Market report includes overview, which interprets value chain structure, industrial environment, regional analysis, applications, market size, and forecast. Continue reading →

This article was originally published here Sci Rep. 2020 Oct 22;10(1):17994. Continue reading →

The Nordic-Baltic-British left main revascularization trial (NOBLE) is a prospective, randomized, multicentre, non-inferiority trial comparing percutaneous coronary angioplasty (PCI) with coronary artery bypass grafting (CABG) for revascularization of patients with unprotected left main coronary artery (LMCA) stenosis. The primary outcome was a combined endpoint of all-cause mortality, stroke, non-procedural myocardial infarction and repeat revascularization. CABG was found to be superior to PCI with respect to the 5-year MACCE rates (28% vs Continue reading →

BACKGROUND The treatment of complex tumors in non-functioning renal transplants requiring surgical extirpation is challenging. Here, we report the largest series of patients who underwent transplant radical nephrectomy for renal cell carcinoma (RCC) and transplant radical nephroureterectomy for urothelial cell carcinoma (UCC) in their transplanted kidneys. Continue reading →

Oct. 26, 2020 12:00 UTC ALAMEDA, Calif.--(BUSINESS WIRE)-- Exelixis, Inc. (NASDAQ: EXEL) today announced enrollment of the first patient into the dose-escalation cohort of the combination arm of the phase 1 trial (NCT03845166) evaluating the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of XL092 alone and in combination with atezolizumab (TECENTRIQ) in patients with advanced solid tumors. Continue reading →